Gutierrez, M., Lam, W., Schoenfeld, A. J., Gubens, M. A., Aggarwal, C., Tan, D. S., Felip, E., Chiu, J. W., Lee, J., Yang, J. C. H., Garon, E. B., Finocchiaro, G., Han, M., Kobie, J., Palcza, J., Dettman, E., Fong, L., Yuan, J., Zhao, B., Herbst, R. S. (2026). Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8584